Skip to main content
Premium Trial:

Request an Annual Quote

Flipping the Script

For years doctors have treated cardiovascular disease by trying to bring down patient's cholesterol levels. Now, some drugmakers are taking the opposite approach.

The Nature News Blog reports on a clinical trial by San Francisco-based pharmaceutical firm Resverlogix that found its BET protein inhibitor RVX-208, raised levels of high-density lipoprotein — aka "good cholesterol."

Because HDL cholesterol works in the body to lower low-density lipoprotein, or "bad cholesterol," pharma researchers hope that by bumping up levels of HDL they can decrease levels of LDL. This could provide an alternative to drugs like statins, which work by targeting LDL production directly.

Just raising HDL levels isn't enough, however. As Nature notes, Pfizer's torcetrapib showed similar effects in phase II studies, but actually worsened patient outcomes in phase III studies. This might be because while the agent caused an increase in HDL production, this new HDL didn't act in typical LDL-lowering fashion.

Resverlogix president Donald MacCaffrey hopes his company's drug will overcome this problem, pointing out that it not only increased HDL levels, but also the levels of the Apo-A1 protein HDL needs to function.

Beyond the agent's potential as a CVD treatment, it has also drawn interest due to its target, Nature says. RVX-208 goes after an epigenetic bromodomain protein, a class of molecule that has been implicated in a range of diseases including cancer and HIV.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.